Delivering Pandemic Vaccines in 100 Days — What Will It Take?
COVID-19, as terrible as it has been, is far from the worst case imaginable. A hundred years ago, the world suffered an influenza pandemic caused by a virus that was four to five times more lethal than COVID-19, and in this century alone we have already experienced outbreaks caused by coronaviruses (SARS and MERS) that are respectively approximately 20 and 70 times as lethal as SARS-CoV-2. The only thing that prevented a catastrophe of unfathomable proportions was that they lacked COVID’s transmissibility.
Vaccines are at the heart of how modern societies counter infectious disease threats. They are our most potent tool against pandemic risks and will be critical to any future response. The faster an effective vaccine is developed and deployed, the faster an incipient pandemic can be contained and controlled.
CAPPY’s aspiration is for the world to be able to respond to the next Disease X with a new vaccine in just 100 days. That’s a little over 3 months to defuse the threat of a pathogen with the potential to cause a pandemic. Coupled with improved surveillance providing earlier detection and warning, and with swift and effective use of non-pharmaceutical interventions such as testing, contact tracing and social distancing to suppress disease transmission, delivering a vaccine in 100 days would give the world a fighting chance to extinguish the existential threat of a future pandemic virus.
CEPI likes to call this its “moonshot” mission—because the goal, while ambitious, is technologically within reach.
To some, the goal sounds impossibly far-fetched – until you break the problems that need to be solved down into manageable chunks and think each one through.
The story of COVID-19 helps us do that—because planning for what is possible in the future is grounded in what we’ve already shown is possible right now.
What’s possible now
If we look across the global portfolio of COVID-19 vaccines—life-saving products that were created from scratch, then manufactured, tested, trialed and brought to bear against a completely new disease—many fast-paced possibilities are clear:
- It’s possible to design a vaccine candidate within 2 days of the genetic sequence of a new virus being published. We know, because that’s what the NIAID Vaccine Research Center did.
- It’s possible to move into first human trials in 66 days from the release of the genetic sequence. We know, because that’s what Moderna did.
- It’s possible to publish the first safety data 63 days after a Phase 1 clinical trial starts. We know, because that’s what Moderna did.
- It’s possible to go from first human clinical trials to vaccine registration in about 7 months. We know, because that’s what Pfizer / BioNTech did.
- And it’s possible to get emergency use approval within 1 day of filing required data with regulators. We know, because that’s what China’s CanSino did.
Had these kinds of milestones been achieved for a single COVID-19 vaccine candidate, then a safe and effective vaccine could in theory have been available for use, based on Phase 3 results, more than two months sooner than in this pandemic. That would have shortened the time from “lab to jab”, or from the publication of a genetic sequence to getting a new vaccine into arms, to less than 9 months. And that’s without any change to our current regulatory paradigm.
Solving the science in advance
Realistically, we can’t create individual new vaccines against 300 or more potential or developing threats, let alone the 1.6 million or so more viral species that may exist in mammal or bird hosts and have yet to be discovered.
But we can develop vaccines against prototypes of these threats. In other words, we can focus our efforts on pathogens that exemplify some or all of the worst traits of a particular viral family.
By solving the problems of vaccine development in advance for a particular pathogen, we prepare to develop vaccines against other members of its family much more rapidly than if we had to start from scratch.
It’s true that the vaccines against the previously unknown SARS CoV-2 virus were developed and deployed at unprecedented speed.
But that achievement didn’t come from nowhere, and that innovation didn’t come out of the blue. Just like other record-breaking human achievements—be they Usain Bolt’s 9.58 second 100m sprint, Dick Rutan and Jeana Yeager’s non-stop flight around the globe, or the Apollo 11 moon landing—they were built on years of hard work: learning, training, experimenting, and testing.
The story of COVID-19 vaccine success shows us how a prototypic-vaccine approach works.
The years of diligent work included painstaking research into vaccines for two closely related coronaviruses, SARS-CoV-1 and MERS-CoV.
Vaccines protect by helping the immune system sense and target invading pathogens. Vaccines typically do this by presenting or fragmenting the pathogen – a so-called “immunogen” – to the immune system to elicit a response before the patient is infected.
For MERS and SARS and SARS-CoV-2, the critical immunogen is the spike protein on the surface of the virus. The spike protein allows each virus to gain entry into cells but is also the major target of the immune system. Through their work on MERS and SARS vaccines, scientists had learned how to elicit a strong immune response against the coronavirus spike protein. These techniques were critical advance knowledge when it came to designing vaccines against the new coronavirus threat of SARS-CoV-2.
Also important in the story of COVID-19 vaccine development were the extraordinary leaps forward in vaccine technology that came to fruition at precisely the right moment.
As part of their work in those years, scientists had honed and developed so-called rapid-response platforms to make “plug-and-play” vaccines. Some used mRNA technology, and others, like the University of Oxford’s ChAdOx, used viral vectors. This meant that when Disease X came and was identified and named as SARS CoV-2—vaccine makers could plug in the genetic code for a part of the novel coronavirus that would trigger an immune response.
These head starts, and the speed with which vaccines were developed as a consequence, have effectively served as ‘proof of concept’ for a prototypic vaccine approach. COVID-19 showed us how it worked as a way of moving fast against a totally new virus, and how it can also work in future against other yet-to-emerge pathogens.
CAPPY’s plan, depending on the complexity and diversity of viruses within a given family, is to create a range of vaccine candidates (perhaps up to 15 in the most complex families) for each family then to select a handful as prototypes to take through rigorous testing including safety and dosing trials in people.
In this way, when a newly emerging virus comes across the frontier – and that is most certainly a “when” and not an “if” – we’ll have banked a vast amount of data on safety and immunogenicity of both the plug-and play platform technology, and the antigens of viruses closely related, if not exactly the same, as the new Disease X.
Ultimately, the gains made through global surveillance and early detection and alerting, coupled with earlier suppression efforts, will mean that on our Day Zero—the start of the 100-day countdown to develop a vaccine to halt an outbreak—case numbers might still be relatively small. And with a vast library of knowledge built up, inserting a genetic sequence for a new and threatening Disease X means we’ll already be months ahead in constraining not just the outbreak and the novel virus, but crucially, its pandemic potential.
Alongside the pre-pandemic scientific problem solving, neutralizing a future Disease X’s pandemic threat will also require the world to agree to some calculated shift on clinical trials and regulation. With the head-start knowledge we’ll have banked in the library of prototype vaccines we can get a head start on designing the trial protocols, getting much of the administrative, and intellectual work done in “peace time”.
CEPI is already working on establishing a global network of clinical trial sites and labs that will need to work with clearly defined “rules of the road” in specific pandemic threat scenarios. This will enable clinical trials to start almost immediately, and mean they can run in parallel with rapid regulatory reviews to assess the benefits of a vaccine balanced against risk of infection and death in a novel outbreak.
If there’s one thing we found out during the COVID-19 crisis, it’s that pandemics are devastatingly expensive. By the end of 2025, it is forecast that COVID-19 will have cost the world $28 trillion over 5 years. That’s $28,000,000,000,000. And that’s just the economic cost. We will never be140988-2 able to quantify the human cost of this pandemic, but its effects will no doubt reverberate for generations.
For sure, being properly prepared doesn’t come cheap. Creating the vaccine library could mean developing as many as 100 prototype vaccines to ensure we’ve got something in the knowledge bank to help us cover almost any threat. Yes, that’s a lot, but it’s finite. It’s also eminently achievable if governments and industry work together. For its part, CEPI has a US$3.5 billion pandemic-busting plan that, over the next 5 years, will kickstart and coordinate this work. Compared with the trillions lost to COVID-19, at $3.5 billion this plan is not only value for money, it’s exactly what the world needs to ensure our children never again face the hardship and loss we’ve had to endure from COVID-19.